<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719966</url>
  </required_header>
  <id_info>
    <org_study_id>MC0834</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC0834</secondary_id>
    <secondary_id>06-004006</secondary_id>
    <nct_id>NCT00719966</nct_id>
  </id_info>
  <brief_title>Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer</brief_title>
  <official_title>Effect of Aromatase Inhibitor Therapy for Breast Cancer on Endothelial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Aromatase inhibitor therapy is used in treating postmenopausal women who have&#xD;
      hormone-dependent breast cancer. It is not yet known what effect aromatase inhibitor therapy&#xD;
      has on blood vessel function.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the effect of aromatase inhibitor therapy on blood&#xD;
      vessel function in postmenopausal women with breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the effect of adjuvant aromatase inhibitor therapy on endothelial function in&#xD;
           postmenopausal women with breast cancer.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 treatment groups&#xD;
      according to breast cancer hormone-receptor status (positive vs negative).&#xD;
&#xD;
        -  Group 1 (hormone receptor-positive): Patients receive aromatase inhibition therapy for&#xD;
           up to 6 months in the absence of unacceptable toxicity.&#xD;
&#xD;
        -  Group 2 (hormone receptor-negative): Patients do not receive adjuvant treatment.&#xD;
&#xD;
      Endothelial function is measured in both groups at baseline and at follow up by the room&#xD;
      temperature peripheral arterial tonometry (RT-PAT) index using the EndoPAT method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2008</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 13, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial dysfunction as a result of aromatase inhibitor therapy</measure>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">109</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1 (hormone receptor-positive)</arm_group_label>
    <description>Patients receive aromatase inhibition therapy for up to 6 months in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (hormone receptor-negative)</arm_group_label>
    <description>Patients do not receive adjuvant treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>Patients receive aromatase inhibition therapy.</description>
    <arm_group_label>Group 1 (hormone receptor-positive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>Patients receive aromatase inhibition therapy.</description>
    <arm_group_label>Group 1 (hormone receptor-positive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Patients receive aromatase inhibition therapy.</description>
    <arm_group_label>Group 1 (hormone receptor-positive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>assessment of therapy complications</intervention_name>
    <description>Endothelial function is measured</description>
    <arm_group_label>Group 1 (hormone receptor-positive)</arm_group_label>
    <arm_group_label>Group 2 (hormone receptor-negative)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with recently diagnosed breast cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of breast cancer&#xD;
&#xD;
          -  Ductal carcinoma in situ (DCIS) allowed provided the patient will not receive&#xD;
             tamoxifen as part of treatment for their cancer&#xD;
&#xD;
          -  May not have had a prior mastectomy with requirement for mastectomy of the&#xD;
             contralateral breast&#xD;
&#xD;
          -  No requirement for axillary lymph node dissection with a history of contralateral&#xD;
             mastectomy and/or contralateral axillary lymph node dissection&#xD;
&#xD;
          -  Hormone receptor status meeting 1 of the following criteria:&#xD;
&#xD;
               -  Hormone receptor negative and not eligible for aromatase inhibitor therapy (AI)&#xD;
&#xD;
               -  Hormone receptor positive and are not receiving an AI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
          -  No known or symptomatic coronary artery disease&#xD;
&#xD;
          -  No significant co-morbidities, including any of the following conditions:&#xD;
&#xD;
               -  Active renal or hepatic disease&#xD;
&#xD;
               -  Known uncontrolled and/or untreated peripheral arterial disease&#xD;
&#xD;
               -  Uncontrolled and/or untreated hypertension&#xD;
&#xD;
               -  Uncontrolled and/or untreated diabetes&#xD;
&#xD;
               -  Uncontrolled and/or untreated hyperlipidemia&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 7 days since prior hormone replacement therapy or hormone-based&#xD;
             contraception&#xD;
&#xD;
          -  More than 12 months since prior and no concurrent tamoxifen or aromatase inhibitor&#xD;
             therapy for this disease&#xD;
&#xD;
          -  More than 12 months since prior and no concurrent chemotherapy for this disease&#xD;
&#xD;
          -  No prior bilateral mastectomy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole P. Sandhu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 19, 2008</study_first_submitted>
  <study_first_submitted_qc>July 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

